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Summary
Background Novel technology has enabled researchers
to better characterize pancreatic cancers at the molec-
ular level. We wanted to explore some of the emerging
discoveries, such as molecular subclassification, use
of liquid biopsy and use of organoids in cancer as-
sessment.
Methods A literature review with a search specific to
the topic, with recent reviews in major journals and
a focus on the last 5 years (until December 2018), was
done.
Results Pancreatic ductal adenocarcinoma (PDAC)
may now be classified into clinical subgroups based
on the predominant genomic profiles, but consen-
sus on one classification system is lacking. Several
subtypes have been suggested, including categories
such as basal-like, stroma-activated, desmoplastic,
pure classical and immune classical types. Further
refinement may translate into clinically meaningful
groups for therapeutic or prognostic purposes. Liquid
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biopsies (by means of circulating cancer cells, cell-
free DNA, exosomes or other constituents of cancer
cells in blood) may aid in earlier diagnosis, define
prognostic groups and even predict therapy response
and resistance. Organoids are increasingly used for
the opportunity to investigate druggable and effective
targets ex vivo and should facilitate personalized and
precise, targeted therapy in the near future. While
immunotherapy has not yet proved to be effective,
a better understanding of molecular subgroups and
specific immune profiles may help identify candidates
for this approach in a more selective approach.
Conclusion Novel molecular techniques have the po-
tential to accelerate the road to improved outcomes
in patients with pancreatic cancer.
Keywords Pancreas · Cancer · Molecular pathology ·
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Main novel aspects
Pancreatic cancer is increasingly understood at the
molecular level, with attempts at subtyping groups with
distinct outcomes and potential for therapeutic targets.
Liquid biopsies are investigated for their ability to
monitor circulating biomarkers and thus potentially de-
tect pancreatic ductal adenocarcinoma (PDAC) at an
earlier stage when disease is resectable with the in-
tent for cure, or to monitor the effect of surgery or
chemotherapy over time.
Previous clinical trials for targeted therapy in PDAC
have so far failed to show substantial survival benefits.
Organoids are increasingly explored for the ability to test
multiple drugs in vivo, in order to better target the drug-
gable points in the individual patient’s cancer.
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Fig. 1 Risk groups and
risk factors for develop-
ing PDAC. Risk popula-
tions are currently restricted
to hereditary genetic syn-
dromes and pancreatic
cysts. The risk of pancreatic
cancer increases with age,
but otherwise the known
risk factors are nonspecific
(and there is an unmet need
for better risk features). An
overall goal is to increase
resectability by earlier di-
agnosis and thus improve
prognosis and survival. This
goal can be facilitated by
identification of novel high-
risk groups that would be
suitable targets for tailored
surveillance. (Reprinted
from K. Søreide [16], Copy-
right (2018), with permission
from Elsevier)
Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains
one of the most lethal of all cancers with mortality
almost equal to the incidence of the disease [1]. PDAC
is refractory to almost all current therapies. Despite
being a devastating disease, only few major changes
to its clinical management have been made over the
past 50 years to improve prognosis, which remains
extremely poor at present [2]. Indeed, due to progress
made in other cancer fields combined with an ag-
ing population, the predictions are that PDAC will
become one of the leading causes of cancer-related
deaths in the next decade [3].
One major factor contributing to the dismal prog-
nosis is the late detection in the majority who present
with the disease: more than half of patients present
with distant metastases at the time of diagnosis; a fur-
ther one third may have locally advanced or, at best,
only borderline resectable disease—hence, usually
less than 20% are amenable to surgical therapy, which
is the only real chance of long-term cure. Data on the
actual resection rates in population-based registries
suggest there is huge variation in clinical practice [4].
PDAC is notoriously resistant to most conventional
chemotherapies, although some novel combinations
have proven promising, such as FOLFIRINOX in the
metastatic setting [5], for borderline disease [6], be-
coming the preferred standard in the adjuvant setting
[7] and, furthermore, now investigated as an neoadju-
vant approach to surgery in upfront resectable disease
[8, 9]. Early diagnosis is hampered by the hard-to-
access gland positioned in the posterior part of the ab-
domen. While novel technologies such as endoscopic
ultrasound (EUS), computed tomography (CT) and
magnetic resonance imaging (MRI) have made visu-
alization of the gland more accurate [10], the criteria
for selection of the population to be screened remains
debatable [11]. Pancreatic cancer is hereditary and
associated with genetic syndromes in but a very small
minority of cases [12–14], and definite risk groups do
not exist except for some cystic lesions [15] that are
known to be premalignant or have malignant poten-
tial (Fig. 1). For the rest of the population, the risk
factors are generic—smoking, obesity and aging are
strongly related to risk of PDAC—and too general to
allow for screening of particular persons at risk [16].
Thus, great interest exists in investigating biological
factors and novel technologies that can facilitate an
earlier diagnosis or be predictive or prognostic for
patients with PDAC. The aim of this narrative review
is to give a brief insight into some of the molecu-
lar mechanisms and technologies that may improve
diagnosis and therapy for PDAC in the near future.
Methods
This narrative review was based on a search of the
PubMed database up to December 20, 2018, with a fo-
cus on articles written in the English language and
published in the past 5 years on the topic of pancre-
atic cancer biology and novel methods for diagnosis
and therapeutic targets.
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Fig. 2 Pancreatic cancer progression model and opportu-
nity for diagnostic and therapeutic interventions. a Pancre-
atic cancer progresses through morphologic changes (PanIN)
that eventually progress to invasive PDAC. Known genetic
alterations occur with each step in the progression. PDAC
is further characterized by a strong desmoplastic reaction
and an intricate crosstalk between cancer cells and the sur-
rounding fibroblasts and immune cells in the stroma that fos-
ters progression, epithelial–mesenchymal transition and even-
tually metastasis. b Pancreatic cancer cells are also char-
acterized by a KRAS-driven extensive metabolic reprogram-
ming. This eventually leads to the clinical phenotype of weight
loss, diabetes, sarcopenia and cachexia often seen in patients
with pancreatic cancer. Increases in fasting blood glucose,
possibly induced by mechanisms such as adrenomedullin-
mediated beta-cell destruction, may serve as an early cue
to pancreatic cancer. c Assuming that these molecular pro-
cesses may occur earlier in carcinogenesis and, thus, may
potentially be excreted in the circulating blood (c), the iden-
tification of such sensitive markers may eventually help to
facilitate earlier diagnosis of pancreatic cancer at a cur-
able stage. CTCs circulating tumour cells, cfDNA cell-free
DNA, miRNA microRNA, PanIN pancreatic intraepithelial neo-
plasia, PDAC pancreatic adenocarcinoma. (Reprinted from
K. Søreide [16], Copyright (2018), with permission from Else-
vier)
Increased biological understanding: precursors
and genomic classification
Several steps towards increased understanding of pan-
creatic cancer have been made over the past decades
[14]. Pancreatic cancer most frequently arises from
precursor lesions, named pancreatic intraepithelial
neoplasia (PanIN) [17]. Pancreatic cancer can also
arise from larger precursor lesions such as intraductal
papillary mucinous neoplasms and mucinous cystic
neoplasms [15]. A stepwise model [18] has been de-
veloped to understand the correlation between early
morphological changes and associated genetic events
[19], as depicted in Fig. 2. With the developments in
sequencing technology, the next generation sequenc-
ing (NGS) platform has allowed for more widespread
and complete characterization of the genomic land-
scape in PDAC. KRAS is the most consistently af-
fected gene (>90% of tumours) harbouring oncogenic
mutations at multiple hotspots, followed closely by
CDKN2A, TP53, and SMAD4/DPC4 [20, 21]. The RAS-
MAPK signalling pathway clearly plays a pivotal role
in PDAC development, as up to 60% of the remaining
KRAS wild-type tumours were shown to carry muta-
tions in alternative members such as BRAF and ERBB2
[21].
The improved understanding gained from im-
proved genome and transcriptome analyses has led
to the characterization of molecular subtypes [22,
23]. The four subtypes, named “squamous”, “pan-
creatic progenitor”, “immunogenic”, and “aberrantly
differentiated endocrine exocrine” (ADEX) correlate
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with histopathological characteristics and clinical
outcomes (e.g. therapeutic response). The squamous
tumours are enriched for TP53 and KDM6A muta-
tions, show upregulation of the TP63N transcriptional
network, and hypermethylation of pancreatic endo-
dermal cell-fate determining genes. The squamous
subclass of PDACs has a poor prognosis [22] and is
predominantly associated with cancers of the pancre-
atic body and tail [24]. Pancreatic progenitor tumours
preferentially express genes involved in early pan-
creatic development (such as FOXA2/3, PDX1 and
MNX1). ADEX tumours displayed upregulation of
genes that regulate networks involved in KRAS acti-
vation, as well as exocrine (NR5A2 and RBPJL) and
endocrine differentiation (NEUROD1 and NKX2-2).
Immunogenic tumours contain upregulated immune
networks including pathways involved in acquired
immune suppression. The four-tier classification
scheme has recently been challenged, namely with
a somewhat different yet overlapping system of five
subtypes suggested, called “pure basal like”, “stroma
activated”, “desmoplastic”, “pure classical” and “im-
mune classical” [25]. Subtyping of PDAC into mean-
ingful clinical subgroups is likely to evolve as we learn
more about the underlying molecular features and as
technical sophistication evolves for further molecular
investigation. At the moment, these molecular classi-
fications are not in clinical use, but may aid in better
substratification for improved understanding of the
underlying biology and clinical behaviour of PDAC.
Also, while the turnaround time and costs of ge-
netic testing have significantly decreased over the past
decade, the practical application of molecular results
to guide individual patient treatment is currently lim-
ited in PDAC. This is in part due to the presence of ac-
tionable targets in a relatively small proportion of pa-
tients, with studies reporting numbers as low as 26%
of cases [26]. On the other hand, the TGCA consor-
tium has recently reported that up to 42% of patients
carry at least one genetic alteration that could grant
inclusion in ongoing clinical trials [21].
A background of bad behaviour in tumour biology
PDACs are known for their desmoplastic growth pat-
tern, consisting of dense fibrotic reaction, inflamma-
tion and poor cellularity. In addition, the poor vessel
density within the tumour partly explains both the
hypoxic environment (lack of nutrients) and the poor
response to most types of chemotherapy. The aggres-
sive nature and early metastatic potential of PDAC
sets in with an aggressive perineural growth pattern
culminating by early invasion and metastasis, even
when cancers are still considered small in size (<2cm)
[16, 27, 28]. Hence, PDACs have a bad biology even
in the very early stages and for rather small tumours
[29]. Better and earlier detection is thus crucial for
improved outcomes, as well as development of tar-
geted drugs that have a higher efficacy to potentially
increase the number of resectable cancers.
Potential for earlier detection
Outside specific genetic syndromes that have a de-
fined risk for PDAC [13], there are no specific risk
factors in clinical use for pancreatic cancer. Several
techniques and novel diagnostic tools are explored for
their ability to detect PDAC at an earlier, resectable
and, still, curable stage in the general population.
Several promising markers and tools have been pro-
posed over the years, but the actual clinical impact
has proven to be slow, with few if any available tests
on the market. Many of the tests available take ad-
vantage of the deranged metabolism in PDAC, with
changes in lipid and protein metabolism as well as
development of hyperglycaemia and pre-diabetes in
the years prior to detection of PDAC.
Among other tests available are endoscopic sam-
pling and measurements of various biomarkers, rang-
ing from proteins in blood or plasma and genetic mu-
tations sampled in cyst fluid or from pancreatic juice
[30] to a proposed “breath test” to measure volatile
organic compounds in patients with PDAC [31]. The
interest in non-invasive tests stems from the difficult
anatomical location of the pancreas, thus the devel-
opment of a clinically available “liquid biopsy” is par-
ticularly of interest (Figs. 2 and 3). This utilises the
exploration of circulating markers in blood, for which
some promising technologies have recently made this
come closer to clinical reality [32–35].
Liquid biopsies
Any bodily fluid can potentially be used for “liquid
biopsy” sampling (e.g. urine, blood, spinal fluid etc),
but peripheral blood is the most intensely investigated
(Fig. 3a) as it contains circulating tumour cells (CTCs)
and circulating tumour-derived cell-free DNA (ctDNA)
that may project biological information of a cancer or
precancer situation. Methods for enrichment and de-
tection of CTCs and ctDNA, their clinical applications
and future opportunities in gastrointestinal cancers
are constantly developing, with refinement of tech-
nology and detection methods [34, 36]. PDAC is an
interesting field for this technology as it may allow for
non-invasive testing for an otherwise hardly accessi-
ble organ [34, 36–40]. Reports on specific mutations
or combinations of markers are promising [35, 37, 39,
41].
Biomarkers that can be detected in peripheral
blood and predict the risk of having resectable cancer
have become closer to reality with recent studies, such
as that of CancerSEEK, showing promising results with
clinical applications [32]. Patients with positive CTCs
prior to resection of PDAC have a poorer prognosis,
even when adjusted for histologically unfavourable
factors [42].
K Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy 129
main topic
Fig. 3 Liquid biopsy and clinical implications for monitor-
ing and therapeutic intervention. a Liquid biopsies (here rep-
resented by blood sample) provide access to the tumour
genome by investigating circulating tumour cells circulating
cell free DNA, exosomes, microRNA and other genomic and
proteomic biomarkers. b Clinical applications of liquid biop-
sies in cancer management. Examples include diagnostic,
prognostic or predictive markers. Therapy effect can be moni-
tored and cancer clones followed for response or resistance
to therapy, either as a before/after effect of surgery, or as
drug-related responses. (Reproduced with permission from
Nordgård O et al. [34]. Copyright (2018), with permission from
Wiley)
Organoids (patient-derived organoids)
Traditional monolayer cell lines have proven useful in
research in a variety of solid malignancies over the
past decades. Nevertheless, these models carry nu-
merous constraints, especially in poorly resectable,
low-cellularity cancers such as PDAC, where the issue
of representativity, both cellular (intratumoural sub-
populations) and at the population level (interpatient
tumour heterogeneity) plays a limiting role. Organoid
culture methods have been recently established from
clinical specimens [43–47] and represent an incredible
advantage over monolayer cell lines: they can be gen-
erated from a resected PDAC in about 2–4 weeks [43],
are amenable to therapeutic screening as well as ge-
netic and biochemical perturbation [48], and are able
to recapitulate interactions between tumour and stro-
mal compartment. Because organoids can be gener-
ated with high efficiency and speed from fine-needle
aspirations, biopsies or resection specimens [43–46],
they can serve as a personal cancer model (Fig. 4). The
biopsied or resected tumour tissue from the individ-
ual patient can be grown and tested for a plethora of
potential drugs, only to choose the drug from samples
that show any response in the organoidmodel. Hence,
the efficacy may be increased by personalizing the
type of therapy given to any patient with PDAC. Per-
sonalized treatment could soon become a more stan-
dard practice by using these cell cultures for exten-
sive molecular diagnosis and drug screening [43, 47,
49]. Drug sensitivity assays can give a clinically action-
able sensitivity profile of a patient’s cancer. Combined
genomic, transcriptomic and therapeutic profiling of
patient-derived organoids can identify molecular and
functional subtypes of pancreatic cancer, predict ther-
apeutic responses and facilitate precision medicine
for patients with PDAC [50].
Molecularly targeted therapies
Targeting specific mutations in pancreatic cancer has
been a matter of research for over several decades
now. The difficulties and obstacles that have been en-
countered during multiple therapeutic approaches to
the RAS/RAF/MEK/ERK pathway are exemplarily on the
so far fruitless way to an effective, personalized treat-
ment [51]. Although more than 90% of PDACs har-
bour a KRAS mutation, inhibition of RAS activation or
its’ downstream signalling with farnesyltransferase in-
hibitors (tipifarnib), MEK 1/2 inhibitors (selumetinib,
trametinib) alone or in combination with EGFR in-
hibitors (erlotinib) either did not show a significant
benefit in survival or were not clinically applicant due
to overlapping toxicities of small molecule inhibitors
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Fig. 4 Model for personalized cancer therapeutics using
organoids. Information from gene sequencing, in vitro drug
analysis and mouse studies can be combined with traditional
molecular analyses, such as immunohistochemistry, to estab-
lish a complete tumour profile. As the establishment and com-
plete analysis of an organoid line takes only a few weeks, the
information could be returned swiftly to the clinic. When pa-
tients develop metastases or the disease relapses, new tu-
mour biopsies can be taken and new organoid lines estab-
lished. (Reproduced with permission from Aberle MR et al.
[48]. Copyright (2018), with permission from Wiley)
and necessary dose reductions. It has been shown
that PDAC possess multiple resistance mechanisms
to overcome selective signalling blockades induced
by these drugs. Recently, a new strategy to control
the “undruggable” KRAS oncogenic pathway has been
postulated by inhibition of SIAH (seven in absentia
homolog), the most downstream gatekeeper in this
deleterious signalling cascade [52]. However, phar-
maceutical evaluation of this potential target is still
pending to date.
According to a recent systematic review [53], an
average yearly number of more than 60 clinical tri-
als have been reported in the last years examining
the efficacy of molecularly targeted therapies in unre-
sectable PDAC, most commonly studying inhibitors of
EGFR, VEGF, RAS pathways and tyrosine kinases. Es-
pecially EGFR inhibitors such as erlotinib, cetuximab
and panitumumab have been extensively studied with
phase I/II trials in this setting, albeit with limited
numbers of patients and without a clear breakthrough
in terms of overall or progression-free survival. Fur-
ther results of phase III studies are therefore eagerly
awaited.
Immunotherapy
As immune evasion is a well-described hallmark of
cancer development, interest in targeting mecha-
nisms that can trigger the immune system to attack
cancer cells has gained increasing interest. Notably,
immunotherapy has proved effective for some can-
cers, and changed the standard of care and life ex-
pectancy for several malignancies, such as cancers of
the lung, head and neck, gastrointestinal tract, and
for some colorectal cancers. Disappointingly, single-
agent immunotherapy has had little effect in PDAC
[54]. Increasing evidence suggests that the PDAC mi-
croenvironment is comprised of an intricate network
of signals between immune cells, PDAC cells and
stroma, resulting in an immunosuppressive environ-
ment resistant to single-agent immunotherapies [54,
55]. It has also been shown that a higher density of
CD3+ T-cells in the stroma is associated with longer
progression-free survival in patients with PDAC [56],
and that combination of mutational profiles and im-
mune markers may define subgroups of patients who
may respond to specific types of therapies [57]. These
findings are promising and may represent potential
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paradigm changes in the approach to how individual
patients with PDAC may be treated in the future.
Conclusion
Pancreatic adenocarcinoma (PDAC) is a lethal ma-
lignancy that is refractory to all current therapies.
Research into the mechanisms driving this cancer is
the key to developing better diagnostic and treatment
options. PDAC may now be classified into clinical
subgroups based on the predominant genomic pro-
files, but consensus on one classification system is
still lacking. Both four and five subtypes have been
suggested, including basal like, stroma activated,
desmoplastic, pure classical and immune classical
types. Further refinement may translate into clinical
meaningful groups for therapeutic or prognostic pur-
poses. Liquid biopsies (by means of circulating cancer
cells, cell-free DNA, exosomes or other constituents
of cancer cells in blood) may aid in earlier diagnosis,
define prognostic groups and even predict therapy
response and resistance. Organoids are increasingly
evaluated for their ability to investigate druggable
and effective targets in any individual patient and
should facilitate personalized and precise, targeted
therapy in the near future. Since most molecularly
targeted therapies have not shown substantial bene-
fit in clinical trials so far, some of the new molecular
techniques raise hope of having the potential to accel-
erate improved outcomes in patients with pancreatic
cancer.
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